MelMarT-II Clinical Trial - update March 2022 MelMarT-II March Update In the UK, there are 9 sites open to recruitment with more due to open shortly and as of the 4th April 2022 there are 60 patients enrolled. MelMarT-II is the Melanoma Margins Trial. It is a randomised study comparing the difference between 1cm and 2cm Wide Local Excision for the treatment of primary cutaneous melanoma. The study hypothesis is, that there is no difference in disease free survival for patients treated with either a 1cm or 2cm excision margin for clinical stage II primary cutaneous melanoma, that a 1cm excision margin will reduce the risk of long-term pain, will reduce surgical complication rates, will have an impact on improved quality of life for patients and will change the use of local healthcare resources. Do you, or someone you know what more information relating to participation? The important study eligibility criteria are as follows: Participants must be over 18 years of age, Participants will already have a Stage 2 primary invasive cutaneous melanoma. This might be, head, arms, legs, body, scalp, limbs. (Note, there will be some areas that will be excluded), There must have been no previous surgeries to remove this melanoma. If you think you are eligible for this trial and would be interested in learning more, please speak to the team or clinician who is responsible for your care. Tune it: We hope you were able to attend the On The Spot Webinar with Melanoma UK entitled ‘Demystifying Clinical Trials and Patient Involvement’. If you could not, be sure to listen to the recording and look out for more talks in the future.